Kitasamycin tartrate

Basic Information

View in Editor

CAS Number

37280-56-1

Molecular Formula

C40H67NO18

Molecular Weight

850 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Aldehydes

Basic Chemical Raw Materials Organic Chemicals Esters

Basic Chemical Raw Materials Organic Chemicals Ethers

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Surfactants Anionic Surfactants

Polymers and Plastics Thermoplastics Polyolefins

Laboratory Chemicals Research Chemicals Biochemical Reagents

Basic Physical Properties

SMILES

View in Editor

CC1CC=CC=CC(C(CC(C(C(C(CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)C)N(C)C)O)CC=O)C)O.C(C(C(=O)O)O)(C(=O)O)O

InChI

InChI=1S/C36H61NO12.C4H6O6/c1-20-17-24(15-16-38)32(33(44-9)26(40)18-27(41)45-21(2)13-11-10-12-14-25(20)39)49-35-30(42)29(37(7)8)31(22(3)47-35)48-28-19-36(5,6)34(43)23(4)46-28;5-1(3(7)8)2(6)4(9)10/h10-12,14,16,20-26,28-35,39-40,42-43H,13,15,17-19H2,1-9H3;1-2,5-6H,(H,7,8)(H,9,10)/b11-10+,14-12+;/t20-,21-,22-,23-,24+,25+,26-,28-,29-,30-,31-,32+,33+,34-,35+;/m1./s1

InChIKey

LCDBILLRZFJKMN-RKYMYSRXSA-N

LogP

-0.0017999999999906424

Topological Polar Surface Area

288.74 Å²

Hydrogen Bond Donor/Acceptor

8 / 19

Complexity

1230

Safety Information

View Safety Information

Hazard Statement

H315 Causes skin irritation
Skin corrosion/irritation

H319 Causes serious eye irritation
Serious eye damage/eye irritation

H335 May cause respiratory irritation
Specific target organ toxicity, single exposure; Respiratory tract irritation

Synonyms & References

English

37280-56-1
kitasamycin tartrate
2,3-dihydroxybutanedioic acid;2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[(2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-[(2R,5S,6R)-5-hydroxy-4,4,6-trimethyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
Kitasamycin tartrate [JAN]
UNII-IPN75MD9DR
EINECS 253-442-3
IPN75MD9DR
2-((4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-(((2R,5S,6R)-5-hydroxy-4,4,6-trimethyltetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-7-yl)acetaldehyde 2,3-dihydroxysuccinate
NS00127383
Leucomycin, (R-(R*,R*))-2,3-dihydroxybutanedioate (salt)
Leucomycin Tartrate
Kitasamycin Tartrate
[(4R,5S,6S,7S,9R,10R,11E,13E,16R)-6-{[(2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-{[(2R,5S,6R)-5-hydroxy-4,4,6-trimethyltetrahydro-2H-pyran-2-yl]oxy}-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-7-yl]acetaldehyde 2,3-dihydroxybutanedioate (salt) (non-preferred name)
Leucomycin (2R,3R)-2,3-dihydroxybutanedioate

MDL Number

MFCD01773593

FAQ

What regulatory guidelines apply to Kitasamycin tartrate (CAS: 37280-56-1)?

Kitasamycin tartrate (CAS: 37280-56-1) is subject to regulatory guidelines such as the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), European Union Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), and requirements set by the U.S. Food and Drug Administration (FDA) and Environmental Protection Agency (EPA). Compliance with these regulations is essential for its safe handling and use.

Are there alternatives to Kitasamycin tartrate (CAS: 37280-56-1) in synthesis?

Alternatives to Kitasamycin tartrate (CAS: 37280-56-1) in synthesis include similar antibiotic derivatives, which may offer different antibacterial properties or improved synthetic routes. Common alternatives include isolevugulinic acid, carvone derivatives, and other macrolides. Researchers often explore these options to optimize antibiotic efficacy and reduce side effects.

What is the market or research trend for Kitasamycin tartrate (CAS: 37280-56-1)?

The market trend for Kitasamycin tartrate (CAS: 37280-56-1) reflects a growing interest in novel antibiotics to combat multi-drug resistant pathogens. Research is focusing on its potential as an alternative to current antibiotics, with studies exploring its mechanism of action and clinical applications. Market dynamics indicate increased investment in developing and validating Kitasamycin tartrate for broader use in healthcare.

How should waste containing Kitasamycin tartrate (CAS: 37280-56-1) be handled?

Waste containing Kitasamycin tartrate (CAS: 37280-56-1) should be managed carefully to prevent environmental contamination. Collection should be done using appropriate packaging to contain any spills. For disposal, professional waste disposal services are recommended. Incineration in compliance with local regulations is an effective method. Environmental protection measures include ensuring no waste is released into waterways and following all local and national disposal guidelines.